Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell)
NCT ID: NCT04636333
Last Updated: 2022-03-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
216 participants
INTERVENTIONAL
2020-10-30
2022-07-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19
NCT04869592
Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old)
NCT04961359
Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial
NCT05599516
Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (≥60 Years Old)
NCT04550351
Clinical Study on the Immune Program of Recombinant Novel Coronavirus（COVID-19) Vaccine (CHO Cell)
NCT05128643
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will set up an Independent Data Monitoring Committee (IDMC) to conduct overall supervision. The IDMC is required to review the unblinded data when a significant event or risk occurs in the study that might cause the study to be suspended.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Middle-dose vaccine (18-59 years) & Two dose regimen
Two doses of middle-dose experimental vaccine at the schedule of day 0, 14.
Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14
Two doses of middle-dose (20µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14.
Middle-dose vaccine (18-59 years) & Three dose regimen
Three doses of middle-dose experimental vaccine at the schedule of day 0, 14 28.
Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28
Three doses of middle-dose (20µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28.
High-dose vaccine (18-59 years) & Two dose regimen
Two doses of high-dose experimental vaccine at the schedule of day 0, 14.
Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14
Two doses of high-dose (40µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHOCell) at the schedule of day 0, 14.
High-dose vaccine (18-59 years) & Three dose regimen
Two doses of High-dose vaccine at the schedule of day 0, 14, 28.
Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28
Three doses of middle-dose (40µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28.
Middle-dose vaccine (> 59 years) & Three dose regimen
Three doses of middle-dose experimental vaccine at the schedule of day 0, 14, 28.
Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28
Three doses of middle-dose (20µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28.
High-dose vaccine (> 59 years) & Three dose regimen
Three doses of high-dose experimental vaccine at the schedule of day 0, 14, 28.
Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28
Three doses of middle-dose (40µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28.
Middle-dose placebo (18-59 years) & Two dose regimen
Two doses of middle-dose placebo at the schedule of day 0, 14.
Two doses of placebo at the schedule of day 0, 14 #middle-dose group#
Two doses of placebo (0.5ml) at the schedule of day 0, 14.
Middle-dose placebo (18-59 years) & Three dose regimen
Three doses of middle-dose placebo at the schedule of day 0, 14, 28.
Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#
Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.
High-dose placebo (18-59 years) & Two dose regimen
Two doses of high-dose placebo at the schedule of day 0, 14.
Two doses of placebo at the schedule of day 0, 14 #High-dose group#
Two doses of placebo (0.5ml) at the schedule of day 0, 14.
High-dose placebo (18-59 years) & Three dose regimen
Three doses of high-dose placebo at the schedule of day 0, 14, 28.
Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group#
Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.
Middle-dose placebo (> 59 years) & Three dose regimen
Three doses of high-dose placebo at the schedule of day 0, 14, 28.
Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#
Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.
High-dose placebo (> 59 years) & Three dose regimen
Three doses of high-dose placebo at the schedule of day 0, 14, 28.
Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group#
Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14
Two doses of middle-dose (20µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14.
Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28
Three doses of middle-dose (20µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28.
Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14
Two doses of high-dose (40µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHOCell) at the schedule of day 0, 14.
Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28
Three doses of middle-dose (40µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28.
Two doses of placebo at the schedule of day 0, 14 #middle-dose group#
Two doses of placebo (0.5ml) at the schedule of day 0, 14.
Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#
Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.
Two doses of placebo at the schedule of day 0, 14 #High-dose group#
Two doses of placebo (0.5ml) at the schedule of day 0, 14.
Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group#
Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The subject can understand and voluntarily sign the informed consent.
* The subject can The subject canprovide legal identification.
Exclusion Criteria
* Have a history of contact with a person infected with SARS-CoV-2(a person with a positive nucleic acid test) in the previous 14 days.
* Patients with fever or respiratory symptoms who have been to middle or high-risk areas in the past 14 days or have exit history, or come from communities with case reports.
* In the past 14 days, there have been 2 or more cases of fever and/or respiratory symptoms in small areas such as homes, offices, school classes, etc.
* Have a history of SARS.
* Have a history of SARS-CoV-2 infection.
* Positive in SARS-CoV-2 IgG or IgM antibody screening.
* Positive in RT-PCR test of SARS-CoV-2 in throat swab.
* Positive in HIVantibody screening.
* Women who are breastfeeding, pregnant, or planning to become pregnant during the study period (based on the subject's self-report and blood pregnancy test results for women of childbearing age), or men who plan to conceive their partners during the study period.
* Subjects with body mass index (BMI) ≥35 kg/m2.
* Have a history of asthma, a history of vaccine or vaccine component allergy, have serious adverse reactions to the vaccine, such as urticaria, dyspnea, angioedema.
* Subjects with congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.
* Subjects with autoimmune diseases or immunodeficiency/immunosuppression.
* Subjects with severe chronic diseases, severe cardiovascular diseases, hypertension and diabetes that cannot be controlled by drugs, liver and kidney diseases, malignant tumors, etc.
* Subjects with severe neurological disease (epilepsy, convulsions or convulsions) or mental illness.
* Subjects with thyroid disease or history of thyroidectomy, no spleen, functional asthenia, and any spleen or splenectomy caused by any condition.
* Abnormal blood coagulation function diagnosed by a doctor (such as coagulation factor deficiency, coagulopathy, abnormal platelet) or obvious bruise or coagulation disorder.
* Have received immunosuppressant therapy, cytotoxic therapy, and inhaled corticosteroids in the past 6 months (excluding corticosteroid spray therapy for allergic rhinitis and surface corticosteroid therapy for acute non-complicated dermatitis).
* Physical examination or chest CT imaging reveals clinically significant abnormalities.
* Abnormal laboratory test results such as hematology and biochemistry that are beyond the reference value range and have clinical significance.
1. Routine blood test: white blood cell count, hemoglobin, platelet count.
2. Blood biochemical index detection: alanine aminotransferase (ALT), aspartate aminotransferase (AST), fasting blood glucose, C-reactive protein, total bilirubin (TBIL), creatinine (CR), creatine phosphokinase (CPK).
3. Urine routine indicators: urine protein (PRO), urine sugar, urine red blood cells.
4. Coagulation function test: prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen (FIB).
* Have a long history of alcohol or drug abuse.
* Received blood products within 3 months before receiving trial vaccine.
* Received other study drugs within 30 days before receiving the trail vaccine.
* Received a live attenuated vaccine within 14 days before receiving the experimental vaccine.
* Received a subunit or inactivated vaccine within 7 days before receiving the experimental vaccine.
* Various acute or chronic diseases occurred in the past 7 days.
* Axillary body temperature\>37.0℃ before vaccination.
* According to the judgment of the investigator, the subject has any other factors that are not suitable for participating in the clinical trial.
If one of the following (1) to (4) adverse events (AE) occurs, the vaccination is prohibited, but other research steps can be continued according to the investigator's judgment; if one of the following (5), (6) adverse events occurs , The investigator will judge whether to inoculate; if one of the following events (7) to (10) occurs, the vaccination can be postponed within the time window specified in the plan.
* (1)The subjects used the same vaccine other than the experimental vaccine during the study.
* (2)Any serious adverse reactions that are causally related to vaccination.
* (3)Severe allergic or hypersensitivity reactions after vaccination (including urticaria/skin rash within 30 minutes after vaccination).
* (4)Any confirmed or suspected autoimmune disease or immunodeficiency disease, including human immunodeficiency virus (HIV) infection.
* (5)Acute or new-onset chronic disease after vaccination.
* (6)Other reactions (including severe pain, severe swelling, severe activity limitation, persistent high fever, severe headache, or other systemic or local reactions) are judged by the investigator.
* (7)Acute illness at the time of vaccination (Acute illness refers to moderate or severe illness with or without fever).
* (8)Axillary temperature \>37.0℃ before vaccination.
* (9)Vaccination of subunit vaccine or inactivated vaccine within 7 days, live attenuated vaccine within 14 days.
* (10)According to the investigator's judgment, the subject has any other factors that are not suitable for vaccination.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jiangsu Province Centers for Disease Control and Prevention
NETWORK
Academy of Military Medical Sciences，Academy of Military Sciences，PLA
UNKNOWN
ZHONGYIANKE Biotech Co, Ltd.
UNKNOWN
LIAONINGMAOKANGYUAN Biotech Co, Ltd
UNKNOWN
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fengcai Zhu, Doctor
Role: PRINCIPAL_INVESTIGATOR
Jiangsu Provincial Center for Disease Control and Prevention
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jiangsu Provincial Center for Diseases Control and Prevention
Nanjing, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Luo D, Pan H, He P, Yang X, Li T, Ning N, Fang X, Yu W, Wei M, Gao H, Wang X, Gu H, Mei M, Li X, Zhang L, Li D, Gao C, Gao J, Fei G, Li Y, Yang Y, Xu Y, Wei W, Sun Y, Zhu F, Hu Z, Wang H. A randomized, double-blind, placebo-controlled phase 1 and phase 2 clinical trial to evaluate efficacy and safety of a SARS-CoV-2 vaccine SCoK in adults. Clin Transl Med. 2022 Sep;12(9):e1016. doi: 10.1002/ctm2.1016.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JSVCT096
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.